Brief: Bellus Health Announces Positive End-Of-Phase 2 Meeting With FDA And Its CALM Phase 3 Program For Blu-5937 In Refractory Chronic Cough

BELLUS Health

12/07/2022 12:21

July 12 (Reuters) - BELLUS Health Inc  BLU.TO :
    * BELLUS HEALTH ANNOUNCES POSITIVE END-OF-PHASE 2 MEETING
WITH THE
FDA AND ITS CALM PHASE 3 PROGRAM FOR BLU-5937 IN REFRACTORY
CHRONIC COUGH
    * BELLUS HEALTH INC - FIRST PATIENT EXPECTED TO BE ENROLLED
IN Q4
OF 2022; TOPLINE RESULTS FROM CALM-1 EXPECTED IN 2H 2024
    * BELLUS HEALTH INC - REACHED ALIGNMENT WITH FDA ON PRIMARY
EFFICACY ENDPOINT OF 24H COUGH FREQUENCY REDUCTION BEING
ASSESSED USING VITALOJAK COUGH MONITORING SYSTEM
    * BELLUS HEALTH INC - FIRST PATIENT EXPECTED TO BE ENROLLED
IN Q4
OF 2022
    * BELLUS HEALTH INC - TOPLINE RESULTS FROM CALM-1 EXPECTED
IN 2H
2024

Source text for Eikon:  ID:nBw4NZkkra 
Further company coverage:  BLU.TO 

 ((Reuters.Briefs@thomsonreuters.com;))